Core Viewpoint - A securities class action lawsuit has been filed against StubHub Holdings, Inc. for allegedly making false and misleading statements in their Offering Documents related to their September 2025 initial public offering [1][2]. Group 1: Allegations Against StubHub - The lawsuit claims that StubHub failed to disclose significant changes in the timing of payments to vendors, which adversely affected their free cash flow [2]. - It is alleged that these undisclosed changes resulted in materially misleading reports regarding StubHub's free cash flow for the trailing 12 months [2]. - The complaint asserts that the positive statements made by StubHub regarding its business operations and prospects were materially false and lacked a reasonable basis due to the undisclosed issues [2]. Group 2: Lead Plaintiff Process - Investors in StubHub have until January 23, 2026, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and represents both individual and institutional investors [4]. - The firm has achieved significant recoveries in securities litigation and has received numerous accolades for its work in this field [4].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit claims securities fraud under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as under Sections 11 and 15 of the Securities Act of 1933 [3]. - Investors have until March 6, 2026, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the termination of the Advance in Aid of Construction Agreement by the First Tenant [7].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Company Overview - Alexandria Real Estate is a real estate investment trust (REIT) focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Financial Performance - Alexandria Real Estate reported disappointing results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on consecutive days [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property, which was deemed not suitable for life science scaling [5][6]. Legal Proceedings - Investors have until January 26, 2026, to request to lead the class action case, which is pending in the U.S. District Court for the Central District of California [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3].

Core Viewpoint - Hagens Berman is investigating Alvotech regarding its disclosures related to manufacturing operations and the regulatory status of its lead biosimilar candidate, AVT05, following a significant stock drop of 34% after receiving a Complete Response Letter from the FDA [1] Company Summary - Alvotech's stock experienced a 34% decline after the announcement of receiving a Complete Response Letter (CRL) from the FDA [1] - The investigation by Hagens Berman focuses on the propriety of Alvotech's disclosures concerning its manufacturing operations [1] - The regulatory status of Alvotech's lead biosimilar candidate, AVT05, is under scrutiny as part of the investigation [1]

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for alleged securities fraud, impacting shareholders who acquired the company's securities between June 4, 2024, and November 19, 2025 [1][2]. Financial Performance - On August 28, 2025, Bath & Body Works reported Q2 2025 earnings per diluted share of $0.30, a decline of 55.8% year over year, and net income of $64 million, down 57.9% year over year [3]. - The company cut its full-year guidance for earnings per diluted share by $0.03, adjusting it to a range of $3.28 to $3.53 [3]. - Following this announcement, the stock price fell by $2.18, or 6.9%, closing at $29.36 per share [4]. Subsequent Developments - On November 20, 2025, Bath & Body Works released Q3 2025 results, reporting a 1% decline in revenue year over year and a 26% drop in net income to $77 million [5]. - The company revised its full-year guidance for net sales from a previously positive range of 1.5%-2.7% to a negative "high single digits" and cut expected earnings per diluted share to "at least $2.83" [5]. - The stock price subsequently fell by $5.22, or 24.8%, closing at $15.82 per share [6]. Allegations in the Lawsuit - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations [7]. - Specific allegations include the failure to disclose that the strategy of pursuing "adjacencies, collaborations, and promotions" was not effective in growing the customer base or delivering expected sales growth [7][8]. - It is claimed that the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [8].

Core Viewpoint - Rezolute, Inc. is under investigation for potential violations of federal securities laws following the announcement of disappointing results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [1][2]. Group 1: Study Results - The Phase 3 sunRIZE study did not meet its primary endpoint, as results were "not statistically significant" compared to the placebo group, which showed a 40% improvement [2]. - The study also failed to meet its key secondary endpoint, which was similarly "not statistically significant" compared to the placebo [2]. - Management expressed disappointment and stated they are conducting a thorough evaluation to understand the study outcomes better [2]. Group 2: Stock Performance - Following the announcement of the study results, Rezolute's stock price plummeted over 89%, opening at $1.21 per share [2].

Core Viewpoint - A class action securities lawsuit has been filed against Blue Owl Capital Inc. due to alleged securities fraud affecting investors between February 6, 2025, and November 16, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that Blue Owl Capital Inc. faced significant pressure on its asset base from redemptions by business development companies, leading to undisclosed liquidity issues [2]. - It is claimed that the company was likely to limit or halt redemptions of certain business development companies, which contradicts the positive statements made by the defendants regarding the company's business and prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until February 2, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to potential violations of federal securities laws [1][3]. Group 1: Company Overview - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI workloads [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI operations [4]. Group 2: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 3: Stock Performance and Impact - Following the announcement of the First Tenant's termination of the construction agreement on December 11, 2025, Fermi's stock dropped by $5.16, or over 33%, from $15.25 to $10.09 per share [7].

Core Insights - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with a focus on its sales practices and reported growth metrics [1][2]. Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and claimed strong demand across all channels, driven by distribution expansion and promotional activities [2]. Sales Growth Concerns - There are concerns that the sales growth reported by BellRing may have been artificially inflated due to temporary trade inventory loading at key retailers, rather than reflecting sustainable consumer demand [2]. Stock Performance - On May 5, 2025, BellRing disclosed that several key retailers had reduced their inventory levels, which would negatively impact growth in Q3 2025. Following this announcement, the stock price fell by $14.88, or 19%, from $78.43 to $63.55 per share [3]. - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].